Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Number of Participants Experiencing Adverse Events

  Measured over: Up to approximately 25 months

• Number of Participants with Abnormal Change in Physical Examinations

  Measured over: Up to approximately 25 months

• Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements

  Measured over: Up to approximately 25 months

• Change From Baseline in Electrocardiograms (ECGs)

  Measured over: Up to approximately 25 months

• Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed

  Measured over: Up to approximately 25 months

• Change from baseline in Best Corrected Visual Acuity (BCVA)

  Measured over: Up to approximately 25 months

• Change in Slit lamp biomicroscopy assessment

  Measured over: Up to approximately 25 months

• Change in Intraocular pressure (IOP)

  Measured over: Up to approximately 25 months

• Change in Lens examination assessment

  Measured over: Up to approximately 25 months

• Change in Ophthalmoscopy assessment

  Measured over: Up to approximately 25 months

• Change in fundus autofluorescence (FAF) imaging assessed by Investigator

  Measured over: Up to approximately 25 months

• Change in Retinal evaluation

  Measured over: Up to approximately 25 months

• Change in spectral domain optical coherence tomography (SD-OCT)

  Measured over: Up to approximately 25 months

• Change in Fluorescein angiography (FA) assessed by Investigator.

  Measured over: Up to approximately 25 months

• Change in choroidal neovascularization (CNV) assessed by Investigator.

  Measured over: Up to approximately 25 months

• Percentage of Participants with Clinically Significant Post-treatment Administration Assessment (study eye only) Findings as Assessed by the Investigator

  Measured over: Up to approximately 25 months

• Maximum Serum Concentration (Cmax) of ABBV-6628

  Measured over: Up to approximately 25 months

• Time to Cmax (Tmax) of ABBV-6628

  Measured over: Up to approximately 25 months

• Area Under the Concentration-Time Curve From zero to the last measurable Timepoint (AUC0-Tlast) of ABBV-6628

  Measured over: Up to approximately 25 months

• Stage 2-Trough serum concentration immediately before next dose (Ctrough) of ABBV-6628

  Measured over: Up to approximately 12 months

Changes Tremor has spotted